Advertisement

Spektrum der Augenheilkunde

, Volume 30, Issue 1, pp 39–47 | Cite as

Leitlinien für die Betreuung und Behandlung von Patienten mit Chorioretinopathia centralis serosa

  • Michael SturEmail author
  • Siamak Ansari-Shahrezaei
  • Anton Haas
  • Michael Tittl
konsensusbericht
  • 178 Downloads

Zusammenfassung

Die Chorioretinopathia centralis serosa (CCS) ist eine meist akut auftretende, exsudative Erkrankung der Makula, die primär junge Männer betrifft, aber auch bei Schwangeren und bei Frauen in der Menopause auftreten kann. In den meisten Fällen kommt es zu einer Spontanremission, die wahrscheinlich durch gezielte Aufklärung des Patienten erleichtert werden kann. Heilt die CCS nicht innerhalb von 3 Monaten ab, sollte die Durchführung einer photodynamischen Therapie mit reduzierter Laser- oder Medikamentendosis erwogen werden. Auf die Verordnung anderer Medikamente sollte verzichtet werden, weil es einerseits keine nachweislich wirksamen Medikamente gibt, andererseits durch Medikamenteneinnahme die wahrscheinlich viel wirksamere Veränderung des Lebensstils in den Hintergrund tritt.

Schlüsselwörter

Chorioretinopathia centralis serosa Stress Cortisontherapie Photodynamische Therapie Laserkoagulation 

Guidelines for the care and treatment of patients with central serous chorioretinopathy

Summary

Central serous chorioretinopathy is an acute exudative disease of the macula, which affects primarily young males, but can also be found in pregnant or postmenopausal females. In most cases there is a spontaneous resorption of acute exudation, which could be further improved by offering specific information to the patient. If the exudation persists longer than 3 months, a photodynamic treatment with reduced laser fluence or half dose of Verteporfin should be offered to the patient. The prescription of other medications should be avoided, since there are no medications with proved efficacy available. Using medication of any kind might also hinder an efficient change of life style, which seems to be the most effective treatment for many cases.

Keywords

Central serous chorioretinopathy Stress Steroid use Photodynamic therapy Laser photocoagulation 

Literatur

  1. 1.
    Gelber GS, Schatz H. Loss of vision due to central serous chorioretinopathy following psychological stress. Am J Psychiatry. 1987;144(1):46–50.PubMedCrossRefGoogle Scholar
  2. 2.
    Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002. Ophthalmology. 2008;115(1):169–73.PubMedCrossRefGoogle Scholar
  3. 3.
    Liew G, Quin G, Gillies M, Fraser-Bell S. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Experiment Ophthalmol. 2013;41(2):201–14.PubMedCrossRefGoogle Scholar
  4. 4.
    Nicholson B, Noble J, Forooghian F, Meyerle C. Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol. 2013;58(2):103–26.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Haimovici R, Rumelt S, Melby J. Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology. 2003;110(4):698–703.PubMedCrossRefGoogle Scholar
  6. 6.
    Pastor-Idoate S, Pena D, Herreras JM. Adrenocortical adenoma and central serous chorioretinopathy: a rare association? Case Rep Ophthalmol. 2011;2(3):327–32.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Miki A, Kondo N, Yanagisawa S, et al. Common variants in the complement factor H gene confer genetic susceptibility to central serous chorioretinopathy. Ophthalmology. 2014;121(5):1067–72.PubMedCrossRefGoogle Scholar
  8. 8.
    de Jong EK, Breukink MB, Schellevis RL, et al. Chronic central serous chorioretinopathy is associated with genetic variants implicated in age-related macular degeneration. Ophthalmology. 2015;122(3):562–70.PubMedCrossRefGoogle Scholar
  9. 9.
    Yannuzzi LA. Central serous chorioretinopathy: a personal perspective. Am J Ophthalmol. 2010;149(3):361–3.PubMedCrossRefGoogle Scholar
  10. 10.
    Spaide RF, Hall L, Haas A, et al. Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina. 1996;16(3):203–13.PubMedCrossRefGoogle Scholar
  11. 11.
    Garg SP, Dada T, Talwar D, Biswas NR. Endogenous cortisol profile in patients with central serous chorioretinopathy. Br J Ophthalmol. 1997;81(11):962–4.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Wakakura M, Ishikawa S. Central serous chorioretinopathy complicating systemic corticosteroid treatment. Br J Ophthalmol. 1984;68(5):329–31.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Bouzas EA, Karadimas P, Pournaras CJ. Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol. 2002;47(5):431–48.PubMedCrossRefGoogle Scholar
  14. 14.
    Chumbley LC, Frank RN. Central serous retinopathy and pregnancy. Am J Ophthalmol. 1974;77(2):158–60.PubMedCrossRefGoogle Scholar
  15. 15.
    Tittl MK, Spaide RF, Wong D, et al. Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol. 1999;128(1):63–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Lovallo WR, Al’Absi M, Blick K, Whitsett TL, Wilson MF. Stress-like adrenocorticotropin responses to caffeine in young healthy men. Pharmacol Biochem Behav. 1996;55(3):365–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Song IS, Shin YU, Lee BR. Time-periodic characteristics in the morphology of idiopathic central serous chorioretinopathy evaluated by volume scan using spectral-domain optical coherence tomography. Am J Ophthalmol. 2012;154(2):366–75e4.PubMedCrossRefGoogle Scholar
  18. 18.
    Mudvari SS, Goff MJ, Fu AD, et al. The natural history of pigment epithelial detachment associated with central serous chorioretinopathy. Retina. 2007;27(9):1168–73.PubMedCrossRefGoogle Scholar
  19. 19.
    Levine R, Brucker AJ, Robinson F. Long-term follow-up of idiopathic central serous chorioretinopathy by fluorescein angiography. Ophthalmology. 1989;96(6):854–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Framme C, Walter A, Gabler B, et al. Fundus autofluorescence in acute and chronic-recurrent central serous chorioretinopathy. Acta Ophthalmol Scand. 2005;83(2):161–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Iida T, Yannuzzi LA, Spaide RF, et al. Cystoid macular degeneration in chronic central serous chorioretinopathy. Retina. 2003;23(1):1–7. (quiz 137-8).PubMedCrossRefGoogle Scholar
  22. 22.
    Quaranta-El Maftouhi M, Maftouhi A E, Eandi CM. Chronic central serous chorioretinopathy imaged by optical coherence tomographic angiography. Am J Ophthalmol. 2015;160(3):581–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Gass JD, Little H. Bilateral bullous exudative retinal detachment complicating idiopathic central serous chorioretinopathy during systemic corticosteroid therapy. Ophthalmology. 1995;102(5):737–47.PubMedCrossRefGoogle Scholar
  24. 24.
    Hee MR, Puliafito CA, Wong C, et al. Optical coherence tomography of central serous chorioretinopathy. Am J Ophthalmol. 1995;120(1):65–74.PubMedCrossRefGoogle Scholar
  25. 25.
    Iida T, Hagimura N, Sato T, Kishi S. Evaluation of central serous chorioretinopathy with optical coherence tomography. Am J Ophthalmol. 2000;129(1):16–20.PubMedCrossRefGoogle Scholar
  26. 26.
    Nicolo M, Zoli D, Musolino M, Traverso CE. Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy. Am J Ophthalmol. 2012;153(3):474–80e1.PubMedCrossRefGoogle Scholar
  27. 27.
    Teke MY, Elgin U, Nalcacioglu-Yuksekkaya P, et al. Comparison of autofluorescence and optical coherence tomography findings in acute and chronic central serous chorioretinopathy. Int. J Ophthalmol. 2014;7(2):350–4.Google Scholar
  28. 28.
    Yalcinbayir O, Gelisken O, Akova-Budak B, et al. Correlation of spectral domain optical coherence tomography findings and visual acuity in central serous chorioretinopathy. Retina. 2014;34(4):705–12.PubMedGoogle Scholar
  29. 29.
    Spaide RF, Klancnik JM Jr. Fundus autofluorescence and central serous chorioretinopathy. Ophthalmology. 2005;112(5):825–33.PubMedCrossRefGoogle Scholar
  30. 30.
    Eandi CM, Piccolino FC, Alovisi C, et al. Correlation between fundus autofluorescence and central visual function in chronic central serous chorioretinopathy. Am J Ophthalmol. 2015;159(4):652–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Iacono P, Battaglia PM, Papayannis A, et al. Acute central serous chorioretinopathy: a correlation study between fundus autofluorescence and spectral-domain OCT. Graefes Arch Clin Exp Ophthalmol. 2015;253(11):1889–97.PubMedCrossRefGoogle Scholar
  32. 32.
    Yoshioka H, Endo Y, Sugita T. [The study of central serous chorioretinopathy by fluorescein fundus angiography. (I)]. Nihon Ganka Gakkai Zasshi. 1969;73(3):299–305.PubMedGoogle Scholar
  33. 33.
    Hayashi K, Hasegawa Y, Tokoro T. Indocyanine green angiography of central serous chorioretinopathy. Int Ophthalmol. 1986;9(1):37–41.PubMedCrossRefGoogle Scholar
  34. 34.
    Piccolino FC, Borgia L. Central serous chorioretinopathy and indocyanine green angiography. Retina. 1994;14(3):231–42.PubMedCrossRefGoogle Scholar
  35. 35.
    Lafaut BA, De Laey JJ. Indocyanine green angiography in central serous chorioretinopathy. Bull Soc Belge Ophtalmol. 1996;262:55–61.PubMedGoogle Scholar
  36. 36.
    Shiraki K, Moriwaki M, Matsumoto M, et al. Long-term follow-up of severe central serous chorioretinopathy using indocyanine green angiography. Int Ophthalmol. 1997;21(5):245–53.PubMedCrossRefGoogle Scholar
  37. 37.
    Chan WM, Lam DS, Lai TY, et al. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with Verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol. 2003;87(12):1453–8.PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Zeligs MA. Central angiospastic retinopathy; a psychosomatic study of its occurrence in military personnel. Psychosom Med. 1947;9(2):110–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Lipowski ZJ, Kiriakos RZ. Psychosomatic aspects of central serous retinopathy. A review and case report. Psychosomatics. 1971;12(6):398–401.PubMedCrossRefGoogle Scholar
  40. 40.
    Bernasconi P, Messmer E, Bernasconi A, Tholen A. Assessment of the sympatho-vagal interaction in central serous chorioretinopathy measured by power spectral analysis of heart rate variability. Graefes Arch Clin Exp Ophthalmol. 1998;236(8):571–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Tewari HK, Gadia R, Kumar D, Venkatesh P, Garg SP. Sympathetic-parasympathetic activity and reactivity in central serous chorioretinopathy: a case-control study. Invest Ophthalmol Vis Sci. 2006;47(8):3474–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Polak BC, Baarsma GS, Snyers B. Diffuse retinal pigment epitheliopathy complicating systemic corticosteroid treatment. Br J Ophthalmol. 1995;79(10):922–5.PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Fok AC, Chan PP, Lam DS, Lai TY. Risk factors for recurrence of serous macular detachment in untreated patients with central serous chorioretinopathy. Ophthalmic Res. 2011;46(3):160–3.PubMedCrossRefGoogle Scholar
  44. 44.
    Werry H, Arends C. Untersuchung zur Objektivierung von Persönlichkeitsmerkmalen bei Patienten mit Retinopathia centralis serosa. Klin Monatsbl Augenheilkd. 1978;172(3):363–70.PubMedGoogle Scholar
  45. 45.
    Yannuzzi LA. Type A behavior and central serous chorioretinopathy. Trans Am Ophthalmol Soc. 1986;84:799–845.PubMedCentralPubMedGoogle Scholar
  46. 46.
    Spahn C, Wiek J, Burger T, Hansen L. Psychosomatic aspects in patients with central serous chorioretinopathy. Br J Ophthalmol. 2003;87(6):704–8.PubMedCentralPubMedCrossRefGoogle Scholar
  47. 47.
    Conrad R, Geiser F, Kleiman A, Zur B, Karpawitz-Godt A. Temperament and character personality profile and illness-related stress in central serous chorioretinopathy. ScientificWorldJournal. 2014;2014:631687.PubMedCentralPubMedCrossRefGoogle Scholar
  48. 48.
    Gass JD. Photocoagulation treatment of idiopathic central serous choroidopathy. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1977;83(3 Pt 1):456–67.PubMedGoogle Scholar
  49. 49.
    Robertson DM, Ilstrup D. Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol. 1983;95(4):457–66.PubMedCrossRefGoogle Scholar
  50. 50.
    Gilbert CM, Owens SL, Smith PD, Fine SL. Long-term follow-up of central serous chorioretinopathy. Br J Ophthalmol. 1984;68(11):815–20.PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Nomura Y, Obata R, Yanagi Y. Intravitreal bevacizumab for iatrogenic choroidal neovascularization due to laser photocoagulation in central serous chorioretinopathy. Jpn J Ophthalmol. 2012;56(3):245–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Cakir M, Cekic O, Yilmaz OF. Photodynamic therapy for iatrogenic CNV due to laser photocoagulation in central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging. 2009;40(4):405–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Chen SN, Hwang JF, Tseng LF, Lin CJ. Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage. Ophthalmology. 2008;115(12):2229–34.PubMedCrossRefGoogle Scholar
  54. 54.
    Lanzetta P, Furlan F, Morgante L, Veritti D, Bandello F. Nonvisible subthreshold micropulse diode laser (810 nm) treatment of central serous chorioretinopathy. A pilot study. Eur J Ophthalmol. 2008;18(6):934–40.PubMedGoogle Scholar
  55. 55.
    Gupta B, Elagouz M, McHugh D, Chong V, Sivaprasad S. Micropulse diode laser photocoagulation for central serous chorio-retinopathy. Clin Experiment Ophthalmol. 2009;37(8):801–5.PubMedCrossRefGoogle Scholar
  56. 56.
    Koss MJ, Beger I, Koch FH. Subthreshold diode laser micropulse photocoagulation versus intravitreal injections of bevacizumab in the treatment of central serous chorioretinopathy. Eye (Lond). 2012;26(2):307–14.CrossRefGoogle Scholar
  57. 57.
    Roisman L, Magalhaes FP, Lavinsky D, et al. Micropulse diode laser treatment for chronic central serous chorioretinopathy: a randomized pilot trial. Ophthalmic Surg Lasers Imaging Retina. 2013;44(5):465–70.PubMedCrossRefGoogle Scholar
  58. 58.
    Malik KJ, Sampat KM, Mansouri A, Steiner JN, Glaser BM. Low-intensity/high-density subthreshold microPulse diode laser for chronic central serous chorioretinopathy. Retina. 2015;35(3):532–6.PubMedCrossRefGoogle Scholar
  59. 59.
    Framme C, Alt C, Schnell S, Brinkmann R, Lin CP. [Selective RPE laser treatment with a scanned cw laser beam in rabbits]. Ophthalmologe. 2005;102(5):491–6.PubMedCrossRefGoogle Scholar
  60. 60.
    Elsner H, Porksen E, Klatt C, et al. Selective retina therapy in patients with central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2006;244(12):1638–45.PubMedCrossRefGoogle Scholar
  61. 61.
    Klatt C, Elsner H, Porksen E, et al. [Selective retina therapy in central serous chorioretinopathy with detachment of the pigmentary epithelium]. Ophthalmologe. 2006;103(10):850–5.PubMedCrossRefGoogle Scholar
  62. 62.
    Framme C, Walter A, Prahs P, Theisen-Kunde D, Brinkmann R. Comparison of threshold irradiances and online dosimetry for selective retina treatment (SRT) in patients treated with 200 nanoseconds and 1.7 microseconds laser pulses. Lasers Surg Med. 2008;40(9):616–24.PubMedCrossRefGoogle Scholar
  63. 63.
    Klatt C, Saeger M, Oppermann T, et al. Selective retina therapy for acute central serous chorioretinopathy. Br J Ophthalmol. 2011;95(1):83–8.PubMedCrossRefGoogle Scholar
  64. 64.
    Yannuzzi LA, Slakter JS, Gross NE, et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina. 2003;23(3):288–98.PubMedCrossRefGoogle Scholar
  65. 65.
    Cardillo Piccolino F, Eandi CM, Ventre L, Rigault de la Longrais RC, Grignolo FM. Photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2003;23(6):752–63.PubMedCrossRefGoogle Scholar
  66. 66.
    Canakis C, Livir-Rallatos C, Panayiotis Z, et al. Ocular photodynamic therapy for serous macular detachment in the diffuse retinal pigment epitheliopathy variant of idiopathic central serous chorioretinopathy. Am J Ophthalmol. 2003;136(4):750–2.PubMedCrossRefGoogle Scholar
  67. 67.
    Battaglia Parodi M, Pozzo S D, Ravalico G. Photodynamic therapy in chronic central serous chorioretinopathy. Retina. 2003;23(2):235–7.PubMedCrossRefGoogle Scholar
  68. 68.
    Rouvas A, Stavrakas P, Theodossiadis PG, et al. Long-term results of half-fluence photodynamic therapy for chronic central serous chorioretinopathy. Eur J Ophthalmol. 2012;22(3):417–22.PubMedCrossRefGoogle Scholar
  69. 69.
    Karakus SH, Basarir B, Pinarci EY, Kirandi EU, Demirok A. Long-term results of half-dose photodynamic therapy for chronic central serous chorioretinopathy with contrast sensitivity changes. Eye (Lond). 2013;27(5):612–20.CrossRefGoogle Scholar
  70. 70.
    Vasconcelos H, Marques I, Santos AR, et al. Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2013;251(7):1697–705.PubMedCrossRefGoogle Scholar
  71. 71.
    Gutierrez-Hernandez JC, Martinez-Camarillo JC, Sadda SR. Long-term follow-up of photoreceptor loss and recovery after half-fluence photodynamic therapy for chronic central serous chorioretinopathy. Retin Cases Brief Rep. 2015;9(2):109–13.PubMedCrossRefGoogle Scholar
  72. 72.
    Tseng CC, Chen SN. Long-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathy. Br J Ophthalmol. 2015;99(8):1070–7.PubMedCrossRefGoogle Scholar
  73. 73.
    Lee JY, Chae JB, Yang SJ, Kim JG, Yoon YH. Intravitreal bevacizumab versus the conventional protocol of photodynamic therapy for treatment of chronic central serous chorioretinopathy. Acta Ophthalmol. 2011;89(3):e293–4.PubMedCrossRefGoogle Scholar
  74. 74.
    Bae SH, Heo JW, Kim C, et al. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Am J Ophthalmol. 2011;152(5):784–92e2.PubMedCrossRefGoogle Scholar
  75. 75.
    Zhao M, Zhang F, Chen Y, et al. A 50 % vs 30 % dose of Verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial. JAMA Ophthalmol. 2015;133(3):333–40.PubMedCrossRefGoogle Scholar
  76. 76.
    Ma J, Meng N, Xu X, Zhou F, Qu Y. System review and meta-analysis on photodynamic therapy in central serous chorioretinopathy. Acta Ophthalmol. 2014;92(8):e594–601.PubMedCrossRefGoogle Scholar
  77. 77.
    Al-Hinai AS, Al-Abri MS. Half-fluence photodynamic therapy to treat chronic central serous chorioretinopathy: a case series. Oman. J Ophthalmol. 2011;4(2):63–6.Google Scholar
  78. 78.
    Smretschnig E, Ansari-Shahrezaei S, Moussa S, et al. Half-fluence photodynamic therapy in acute central serous chorioretinopathy. Retina. 2012;32(10):2014–9.PubMedCrossRefGoogle Scholar
  79. 79.
    Lim SH, Chang W, Sagong M. Efficacy of half-fluence photodynamic therapy depending on the degree of choroidal hyperpermeability in chronic central serous chorioretinopathy. Eye (Lond). 2013;27(3):353–62.CrossRefGoogle Scholar
  80. 80.
    Nicolo M, Eandi CM, Alovisi C, et al. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol. 2014;157(5):1033–7.PubMedCrossRefGoogle Scholar
  81. 81.
    Chan WM, Lai TY, Lai RY, Liu DT, Lam DS. Half-dose Verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology. 2008;115(10):1756–65.PubMedCrossRefGoogle Scholar
  82. 82.
    Chan WM, Lai TY, Lai RY, et al. Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. Retina. 2008;28(1):85–93.PubMedCrossRefGoogle Scholar
  83. 83.
    Koytak A, Erol K, Coskun E, et al. Fluorescein angiography-guided photodynamic therapy with half-dose Verteporfin for chronic central serous chorioretinopathy. Retina. 2010;30(10):1698–703.PubMedCrossRefGoogle Scholar
  84. 84.
    Kim KS, Lee WK, Lee SB. Half-dose photodynamic therapy targeting the leakage point on the fluorescein angiography in acute central serous chorioretinopathy: a pilot study. Am J Ophthalmol. 2014;157(2):366–73e1.PubMedCrossRefGoogle Scholar
  85. 85.
    Shiode Y, Morizane Y, Kimura S, et al. Comparison of halving the irradiation time or the Verteporfin dose in photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2015. (Epub ahead of print).Google Scholar
  86. 86.
    Kim YK, Ryoo NK, Woo SJ, Park KH. Comparison of visual and anatomical outcomes of half-fluence and half-dose photodynamic therapy in eyes with chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2015. (Epub ahead of print).Google Scholar
  87. 87.
    Silva RM, Ruiz-Moreno JM, Gomez-Ulla F, et al. Photodynamic therapy for chronic central serous chorioretinopathy: a 4-year follow-up study. Retina. 2013;33(2):309–15.PubMedCrossRefGoogle Scholar
  88. 88.
    Lim JI, Glassman AR, Aiello LP, et al. Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmology. 2014;121(5):1073–8.PubMedCrossRefGoogle Scholar
  89. 89.
    Yaman A, Arikan G, Saatci AO, Cingil G. Choroidal neovascularization following photodynamic therapy in a patient with chronic central serous chorioretinopathy. Bull Soc Belge Ophtalmol. 2007(303):69–73.Google Scholar
  90. 90.
    Tatham A, Macfarlane A. The use of propranolol to treat central serous chorioretinopathy: an evaluation by serial OCT. J Ocul Pharmacol Ther. 2006;22(2):145–9.PubMedCrossRefGoogle Scholar
  91. 91.
    Fabianova J, Porubska M, Cepilova Z. [Central serous chorioretinopathy-treatment with beta blockers]. Cesk Slov Oftalmol. 1998;54(6):401–4.PubMedGoogle Scholar
  92. 92.
    Chrapek O, Spackova K, Rehak J. [Treatment of central serous chorioretinopathy with beta blockers]. Cesk Slov Oftalmol. 2002;58(6):382–6.PubMedGoogle Scholar
  93. 93.
    Chrapek O, Jirkova B, Kandrnal V, Rehak J, Sin M. Treatment of central serous chorioretinopathy with beta-blocker metipranolol. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159(1):120–3.PubMedGoogle Scholar
  94. 94.
    Caccavale A, Romanazzi F, Imparato M, et al. Low-dose aspirin as treatment for central serous chorioretinopathy. Clin Ophthalmol. 2010;4:899–903.PubMedCentralPubMedCrossRefGoogle Scholar
  95. 95.
    Caccavale A, Romanazzi F, Imparato M, et al. Central serous chorioretinopathy: a pathogenetic model. Clin Ophthalmol. 2011;5:239–43.PubMedCentralPubMedCrossRefGoogle Scholar
  96. 96.
    Chong CF, Yang D, Pham TQ, Liu H. A novel treatment of central serous chorioretinopathy with topical anti-inflammatory therapy. BMJ Case Rep. 2012;2012:pii.Google Scholar
  97. 97.
    Alkin Z, Osmanbasoglu OA, Ozkaya A, Karatas G, Yazici AT. Topical nepafenac in treatment of acute central serous chorioretinopathy. Med Hypothesis Discov Innov Ophthalmol. 2013;2(4):96–101.PubMedCentralPubMedGoogle Scholar
  98. 98.
    Pikkel J, Beiran I, Ophir A, Miller B. Acetazolamide for central serous retinopathy. Ophthalmology. 2002;109(9):1723–5.PubMedCrossRefGoogle Scholar
  99. 99.
    Nielsen JS, Jampol LM. Oral mifepristone for chronic central serous chorioretinopathy. Retina. 2011;31(9):1928–36.PubMedCrossRefGoogle Scholar
  100. 100.
    Ravage ZB, Packo KH, Creticos CM, Merrill PT. Chronic central serous chorioretinopathy responsive to rifampin. Retin Cases Brief Rep. 2012;6(1):129–32.PubMedCrossRefGoogle Scholar
  101. 101.
    Nelson J, Saggau DD, Nielsen JS. Rifampin induced hepatotoxicity during treatment for chronic central serous chorioretinopathy. Retin Cases Brief Rep. 2014;8(1):70–2.PubMedCrossRefGoogle Scholar
  102. 102.
    Shulman S, Goldenberg D, Schwartz R, et al. Oral Rifampin treatment for longstanding chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2015. (Epub ahead of print).Google Scholar
  103. 103.
    Forooghian F, Meleth AD, Cukras C, et al. Finasteride for chronic central serous chorioretinopathy. Retina. 2011;31(4):766–71.PubMedCentralPubMedGoogle Scholar
  104. 104.
    Bousquet E, Beydoun T, Rothschild PR, et al. Spironolactone for nonresolving central serous chorioretinopathy: a randomized controlled crossover study. Retina. 2015. (Epub ahead of print).Google Scholar
  105. 105.
    Ryan EH, Pulido CM. Central serous chorioretinopathy treatment with spironolactone: a challenge-rechallenge case. Retin Cases Brief Rep. 2015;9(3):235–8.PubMedCrossRefGoogle Scholar
  106. 106.
    Singh RP, Sears JE, Bedi R, et al. Oral eplerenone for the management of chronic central serous chorioretinopathy. Int. J Ophthalmol. 2015;8(2):310–4.Google Scholar
  107. 107.
    Salz DA, Pitcher JD 3rd, Hsu J, et al. Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series. Ophthalmic Surg Lasers Imaging Retina. 2015;46(4):439–44.PubMedCrossRefGoogle Scholar
  108. 108.
    Breukink MB, den Hollander AI, Keunen JE, Boon CJ, Hoyng CB. The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy. Acta Ophthalmol. 2014;92(6):e488–90.PubMedCrossRefGoogle Scholar
  109. 109.
    Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol. 2007;143(6):977–83.PubMedCrossRefGoogle Scholar
  110. 110.
    Chung YR, Seo EJ, Lew HM, Lee KH. Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review. Eye (Lond). 2013;27(12):1339–46.CrossRefGoogle Scholar
  111. 111.
    Kim DY, Joe SG, Yang SJ, et al. The association between choroidal thickness variations and response to intravitreal bevacizumab in central serous chorioretinopathy. Korean J Ophthalmol. 2015;29(3):160–7.PubMedCentralPubMedCrossRefGoogle Scholar
  112. 112.
    Kim GA, Rim TH, Lee SC, et al. Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients. Eye (Lond). 2015;29(6):732–40. (quiz 41).CrossRefGoogle Scholar
  113. 113.
    Altun A, Kurna SA, Olcaysu OO, et al. Success of ranibizumab in central serous chorioretinopathy resistant to bevacizumab. J Ocul Pharmacol Ther. 2014;30(10):842–6.PubMedCrossRefGoogle Scholar
  114. 114.
    Pitcher JD 3rd, Witkin AJ, DeCroos FC, Ho AC. A prospective pilot study of intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy: the CONTAIN study. Br J Ophthalmol. 2015;99(6):848–52.PubMedCrossRefGoogle Scholar
  115. 115.
    Broadhead GK, Chang A. Intravitreal aflibercept for choroidal neovascularisation complicating chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2015;253(6):979–81.PubMedCrossRefGoogle Scholar
  116. 116.
    Cunneen TS, Tridgell D. The dexamethasone suppression test for the diagnosis of Cushing syndrome in a patient with central serous chorioretinopathy. Retin Cases Brief Rep. 2013;7(2):143–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2015

Authors and Affiliations

  • Michael Stur
    • 1
    • 4
    Email author
  • Siamak Ansari-Shahrezaei
    • 2
    • 4
  • Anton Haas
    • 3
    • 4
  • Michael Tittl
    • 4
  1. 1.WienÖsterreich
  2. 2.Augenabteilung der KA Rudolfstiftung der Stadt WienWienÖsterreich
  3. 3.Universitätsaugenklinik der Medizinische Universität GrazGrazÖsterreich
  4. 4.Für die Netzhautkommission der Österreichischen Ophthalmologischen GesellschaftWienÖsterreich

Personalised recommendations